3SBio a Top Chinese Biotech
3SBio Inc. (SSRX - Snapshot Report) is a China-based biotech company focused on developing and marketing therapeutics for nephrology, oncology and cancer supportive care. The company's flagship product, EPIAO, is the number 1 brand in the erythropoietin (EPO) market.
Second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company's top line growth. Recent deals with US-based AMAG Pharmaceuticals Inc. (AMAG - Analyst Report) will boost its expansion into the IV Iron market, which will sustain long-term growth.
We believe shares of 3SBio are undervalued and are attractive at current levels. We maintain a Buy rating with a 6 to 12 month target price of $10.
Read the full analyst report on SSRX
Read the full analyst report on AMAG
|
|
|
Share |
RSS |
Rate Pos |
Rate Neg |
Comment |
|
|
||||||
Loading Stories...Most Popular on Zacks.com
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Nov 08, 2009 07:55 am ET |
Sponsored Links

Sponsored Links 
1.21 %

[CLICK TO CLOSE X]